SCHEMBL6069045

SCHEMBL6069045

Cc1oc(-c2ccc(C(F)(F)F)cc2)nc1-c1ccc(-c2ccc(C=O)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 8/20 0.61
IKBKB O14920 1/20 0.41
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
NOTUM Q6P988 1/20 0.40
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
PPARA Q07869 1/20 0.38
PPARD Q03181 2/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
BACE1 P56817 1/20 0.38
PPARG P37231 1/20 0.38
BRD4 O60885 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6069381 0.84 PTPN1 (0.61) PTPN1IKBKBLMNATHRBCA1
SCHEMBL6069378 0.84 PTPN1 (0.61) PTPN1IKBKBLMNATHRBCA1
SCHEMBL6068841 0.82 PTPN1 (0.73) PTPN1IKBKBLMNATHRBPPARD
SCHEMBL7737825 0.82 SMO (0.51) PTPN1BRD4
SCHEMBL6069089 0.81 PTPN1 (0.70) PTPN1IKBKBLMNATHRBNOTUM
SCHEMBL6069281 0.80 PTPN1 (0.67) PTPN1MAOB
SCHEMBL10748706 0.79 PTPN1 (0.48) PTPN1IKBKBLMNATHRBNOTUM
SCHEMBL9260216 0.77 PPARG (0.53) PTPN1PPARAPPARDPPARG
SCHEMBL2268468 0.76 KIF11 (0.56) CA1CA2
SCHEMBL6069138 0.76 PTPN1 (0.61) PTPN1IKBKBLMNATHRBPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7141672-B2 Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2006-11-28 US disclosed
US-20040147755-A1 Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2004-07-29 US disclosed
US-6699896-B1 METABOLIC DISORDERS, ANTIDIABETIC AGENTS; OBESITY WYETH 2004-03-02 US disclosed
EP-1077958-A1 OXAZOLE-ARYL-CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
WO-1999058511-A1 OXAZOLE-ARYL-CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147755-A1 Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, GCKR PTPN1 870/4885IKBKB 2010/4885LMNA 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.